| (210) | Number of the EPO application | 17829372 |
| (220) | Filing date of the EPO application | 2017.12.05 |
| (80) | EPO patent specification publication (B) | EPB nr. 32/2021, 2021.08.11 |
| (110) | EPO patent number | 3551617 |
| (11) | Number of the document | MD 3551617 T2 |
| (21) | Number of the application | e 2019 1169 |
| (71) | Name(s) of applicant(s), code of the country | CoLucid Pharmaceuticals, Inc., US; |
| (72) | Name(s) of inventor(s), code of the country | ALLIERI Brigida, US;
FAGAN Paul, US;
SHARP Emma, GB;
SKWIERCZYNSKI Raymond D., US; |
| (73) | Name(s) of owner(s), code of the country | CoLucid Pharmaceuticals, Inc., US; |
| (54) | Title of the invention | Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists |
| (13) | Kind-of-document code | T2 |
| (51) | International Patent Classification | C07D 401/06 (2006.01.01); A61K 31/444 (2006.01.01); A61P 25/06 (2006.01.01) |
| (19) | Country | US |
| (41) | Date of publication of the application | 2019.11.30 |
| (49) | Date of publication of the translation of the validated European patent specification | 2021.12.31 |
| (30) | Priority | 201662430662 P, 2016.12.06, US |
| (74) | Patent attorney | (Procedură) PARASCA Dumitru, str. Eminescu nr. 40, ap. 13, c/p 28, MD-2012, Chişinău, Republica Moldova |
| (86) | International application | PCT/US2017/064652, 2017.12.05 |
| (87) | International publication | WO 2018/106657, 2018.06.14 |